IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer
1. First patient enrolled in IDE397 and Trodelvy NSCLC trial. 2. Combination targets MTAP-deletion tumors, critical area with no approved therapies. 3. Trial results could validate IDEAYA's clinical strategy across multiple solid tumors. 4. Collaboration with Gilead bolsters IDEAYA’s drug development capabilities. 5. Safety and efficacy of the combination remain unestablished and under investigation.